sTREM2 (Soluble TREM2) - Microglial Biomarker

sTREM2 (Soluble TREM2)

sTREM2 (soluble Triggering Receptor Expressed on Myeloid Cells 2) is a microglial biomarker that reflects microglial activation in Alzheimer's disease and other neurodegenerative disorders[@ulrich2016].

Overview

TREM2 is a cell surface receptor expressed primarily on microglia in the central nervous system. The soluble form, sTREM2, is generated through shedding of the extracellular domain by proteolytic cleavage. CSF sTREM2 levels provide insights into microglial activity and have emerged as an important biomarker for neuroinflammation in AD and other neurodegenerative diseases[@hickman2023].

Structure and Function

Molecular Characteristics

| Property | Value |
|----------|-------|
| Gene | TREM2 |
| Protein Name | Soluble TREM2 |
| UniProt ID | Q9NZC2 (TREM2) |
| Molecular Weight | ~25 kDa (soluble form) |
| Cell Type Expression | Microglia |
| Ligands | Lipids, apolipoproteins, Aβ |

TREM2 Biology

TREM2 plays critical roles in microglial function[@wang2015]:

Phagocytosis: Enables microglia to clear Aβ plaques and cellular debris

Cell Survival: Provides trophic support for microglia

Inflammatory Response: Regulates cytokine production

Metabolic Function: Supports microglial energy metabolism

Synaptic Pruning: Involved in developmental and disease-related pruning

sTREM2 Generation

Proteolytic Processing

sTREM2 is generated through[@wunderlich2013]:

...

sTREM2 (Soluble TREM2)

sTREM2 (soluble Triggering Receptor Expressed on Myeloid Cells 2) is a microglial biomarker that reflects microglial activation in Alzheimer's disease and other neurodegenerative disorders[@ulrich2016].

Overview

TREM2 is a cell surface receptor expressed primarily on microglia in the central nervous system. The soluble form, sTREM2, is generated through shedding of the extracellular domain by proteolytic cleavage. CSF sTREM2 levels provide insights into microglial activity and have emerged as an important biomarker for neuroinflammation in AD and other neurodegenerative diseases[@hickman2023].

Structure and Function

Molecular Characteristics

| Property | Value |
|----------|-------|
| Gene | TREM2 |
| Protein Name | Soluble TREM2 |
| UniProt ID | Q9NZC2 (TREM2) |
| Molecular Weight | ~25 kDa (soluble form) |
| Cell Type Expression | Microglia |
| Ligands | Lipids, apolipoproteins, Aβ |

TREM2 Biology

TREM2 plays critical roles in microglial function[@wang2015]:

Phagocytosis: Enables microglia to clear Aβ plaques and cellular debris

Cell Survival: Provides trophic support for microglia

Inflammatory Response: Regulates cytokine production

Metabolic Function: Supports microglial energy metabolism

Synaptic Pruning: Involved in developmental and disease-related pruning

sTREM2 Generation

Proteolytic Processing

sTREM2 is generated through[@wunderlich2013]:

ADAM10/ADAM17 Cleavage: Shedding of extracellular domain

Alternative Splicing: Produces soluble isoforms

Release from Cell Surface: Proteolytic release from microglia

Biological Significance

• Microglial Activation Marker: sTREM2 reflects TREM2-expressing microglia
• Functional Implications: May have both protective and pathogenic roles
• Disease Stage Effects: Levels vary across AD disease progression

Role as a Biomarker

CSF sTREM2 in Alzheimer's Disease

sTREM2 levels in CSF show a characteristic pattern in AD[@surezcalvet2016][@piccio2017]:

• Increased in AD: Elevated compared to healthy controls
• MCI Stage: Increases in prodromal AD
• Disease Progression: Correlates with clinical decline
• Plaque Pathology: Associated with amyloid plaque burden

Clinical Significance

| Condition | CSF sTREM2 Level | Clinical Interpretation |
|-----------|------------------|------------------------|
| Alzheimer's Disease | ↑ Elevated | Microglial activation |
| MCI due to AD | ↑ Elevated | Early microglial response |
| Amyloid-Positive Controls | ↑ Elevated | Preclinical activation |
| Frontotemporal Dementia | Variable | Variable microglial involvement |
| Parkinson's Disease | Normal to slightly elevated | Less prominent neuroinflammation |
| Healthy Controls | Low baseline | Baseline microglial activity |

Mechanisms of sTREM2 Elevation

Disease-Associated Microglia (DAM)

sTREM2 reflects the recruitment and activation of DAM[@kerenshaul2017]:

Microglial Proliferation: Expansion of microglial population

DAM Transition: Conversion to disease-associated phenotype

Plaque Response: Reactive microglial recruitment to Aβ

Synaptic Injury Response: Microglial activation to synaptic damage

Genetic Associations

TREM2 Variants affect sTREM2 levels[@sims2017]:

| TREM2 Variant | sTREM2 Effect | AD Risk |
|---------------|---------------|---------|
| R47H (Risk) | Reduced | Increased |
| R62H (Risk) | Reduced | Increased |
| Loss-of-function | Reduced | Increased |
| Protective Variants | Increased | Reduced |

Diagnostic Utility

Biomarker Combinations

sTREM2 is combined with other AD biomarkers:

| Biomarker | Primary Target | Clinical Utility |
|-----------|---------------|------------------|
| sTREM2 | Microglial activation | Neuroinflammation |
| p-tau | Tau pathology | Core AD biomarker |
| Aβ42 | Amyloid pathology | Core AD biomarker |
| NfL) | Axonal injury | Disease progression |

Performance

• AD vs. Controls: AUC ~0.70-0.80
• With p-tau/Aβ42: Improved discrimination
• Prognostic Value: Predicts progression from MCI to AD

Therapeutic Implications

TREM2-Targeting Therapies

sTREM2 is relevant to emerging AD treatments[@schlepckow2023]:

TREM2 Agonists: Enhancing microglial function

Antibody Therapies: Anti-TREM2 antibodies in development

Gene Therapy: TREM2 expression modulation

Biomarker Utility

• Patient Selection: Identifying microglial activation
• Treatment Monitoring: Assessing therapeutic response
• Mechanism of Action: Demonstrating microglial engagement

Detection Methods

| Method | Sample | Advantages |
|--------|--------|------------|
| ELISA | CSF | Standardized, high throughput |
| Simoa | CSF, Plasma | Ultra-sensitive |
| Western Blot | CSF | Confirms isoform identity |
| Mass Spectrometry | CSF | High specificity |

Research Directions

Current Questions

sTREM2 Function: What are the biological activities of sTREM2?

Therapeutic Targeting: How to modulate TREM2 for benefit?

Blood-Based Testing: Can plasma sTREM2 be reliably measured?

Stage-Specific Effects: How do levels change across disease stages?

Future Applications

Multimarker Panels: Combining with p-tau and NfL

Clinical Trials: Patient stratification and monitoring

Precision Medicine: Personalized approaches based on microglial status

Cross-Links

Related Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Microglia](/cell-types/microglia)
• [TREM2](/genes/trem2)
• [Cerebrospinal Fluid Biomarkers](/diagnostics/csf-biomarkers) - Sample type

Related Proteins

• [GFAP](/mechanisms/dopaminergic-neuron-vulnerability)
• [YKL](/mechanisms/dopaminergic-neuron-vulnerability)
• [NfL](/mechanisms/dopaminergic-neuron-vulnerability)

External Links

• [PubMed - sTREM2 Biomarker](https://pubmed.ncbi.nlm.nih.gov/?term=sTREM2+biomarker+neurodegeneration)
• [NIH - Biomarker Research](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581152/)
• [Nature - Neurodegeneration Biomarkers](https://www.nature.com/articles/nrneurol.2017.21)

Background

The study of Strem2 (Soluble Trem2) Microglial Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Microglial Activation Pathway

Disease Association

| Condition | sTREM2 Level | Interpretation |
|-----------|--------------|----------------|
| Healthy | Baseline | Normal microglial function |
| Preclinical AD | Elevated | Early microglial response |
| MCI-AD | Higher | Active disease-associated microglia |
| AD Dementia | Variable | Disease stage dependent |
| Young individuals | Lower | Developmental microglial state |

Microglial Activation Pathway

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

References

[Ulrich JD, Holtzman DM, TREM2 in Alzheimer's disease: A microglia-specific receptor that opens new avenues for understanding AD pathogenesis (2016)]([DOI:10.1016/j.neuron.2016.06.032](https://doi.org/10.1038/s41583-023-00668-4)

[Wang Y, Cella M, Mallinson K, et al, TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model (2015)]([DOI:10.1016/j.cell.2015.01.049](https://doi.org/10.1074/jbc.M113.517540)

[Suárez-Calvet M, Araque Caballero MA, Brendel M, et al, Early increases in sTREM2 biomarker networks preceding tau pathology in Alzheimer's disease (2016)]([DOI:10.1093/brain/aww150](https://doi.org/10.3233/JAD-160452)

[Keren-Shaul H, Spinrad A, Weiner A, et al, A unique microglia type associated with restricting development of Alzheimer's disease (2017)]([DOI:10.1016/j.cell.2017.05.018](https://doi.org/10.1038/s41593-023-01269-7)